News | May 14, 2022
CCMB develops India’s first mRNA vaccine technology
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
Boehringer Ingelheim continues to innovate to enhance the customer experience and improve animal health and well-being
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
As part of the celebrations, the Institute organised a series of activities in the run up to International Nurses Day which is observed on 12th May every year
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
The company also raised Rs 270 crore investment from Temasek in 2019
Cipla has reported consolidated financial results for the period ended March 31, 2022
Subscribe To Our Newsletter & Stay Updated
